Stilla Technologies

Stilla Technologies, founded in 2013 as a multiplex digital PCR company, is now part of Bio-Rad Laboratories. With more than a decade of experience transforming complex genomic data into actionable insights, Stilla supports a wide range of research and clinical applications - including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing.

Stilla's groundbreaking Crystal Digital PCR solution, the QX700 TM series systems (formerly the Nio system), is the industry's first digital PCR system featuring six fluorescent channels - offering the highest multiplexing and detection capacity available to biomedical researchers and clinicians.

• Liquid biopsy
• Cell & Gene Therapy
• Environmental & Food Testing
• Pathogen Detection
• Organ Transplant, Rare Event Detection, & Oncology

In partnership with Bio-Rad Laboratories, we are committed to advancing health research through high-precision genetic analysis solutions for researchers and clinicians worldwide.